Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Short term Debt (2017 - 2025)

Serina Therapeutics' Short term Debt history spans 9 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Short term Debt fell 72.4% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $2.9 million, down 72.4%, while the annual FY2022 figure was $7.6 million, 10822.86% up from the prior year.
  • Short term Debt for Q3 2025 was $2.9 million at Serina Therapeutics, down from $10.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $22.9 million in Q2 2023 and bottomed at $59000.0 in Q3 2022.
  • The 5-year median for Short term Debt is $6.7 million (2022), against an average of $7.4 million.
  • The largest YoY upside for Short term Debt was 10822.86% in 2022 against a maximum downside of 98.95% in 2022.
  • A 5-year view of Short term Debt shows it stood at $70000.0 in 2021, then surged by 10822.86% to $7.6 million in 2022, then tumbled by 80.04% to $1.5 million in 2023, then surged by 585.58% to $10.5 million in 2024, then crashed by 72.4% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Short term Debt are $2.9 million (Q3 2025), $10.5 million (Q3 2024), and $10.4 million (Q2 2024).